SelectQuote Förvaltning
Förvaltning kriterier kontrolleras 2/4
SelectQuote VD är Tim Danker, utsedd i Jan 2017, har en mandatperiod på 9.67 år. totala årliga ersättningen är $ 3.49M, bestående av 16% lön 84% bonusar, inklusive företagsaktier och optioner. äger direkt 1.69% av företagets aktier, värda $ 1.49M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4.9 år respektive 5.3 år.
Viktig information
Tim Danker
Verkställande direktör
US$3.5m
Total ersättning
| VD-lön i procent | 15.97% |
| Anställning som VD | 9.7yrs |
| Ägande av VD | 1.7% |
| Ledningens genomsnittliga anställningstid | 4.9yrs |
| Styrelsens genomsnittliga mandatperiod | 5.3yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Sep 09
SLQT: Softer Revenue Outlook And FY26 Guidance Will Shape Future P/E
Analysts have reduced their price target on SelectQuote from $5 to $3, citing softer revenue expectations and lower projected fiscal 2027 revenue of about $1.4b and adjusted EBITDA of roughly $98.8m compared with prior estimates. What’s in the News for SelectQuote SelectQuote issued earnings guidance for fiscal 2026, with revenue expected in a range of $1.35 billion to $1.45 billion.
Uppdatering av berättelse • Aug 26
SLQT: Improved Profitability And Reset Expectations Will Support Future Upside
Analysts have trimmed their fair value estimate for SelectQuote, with the price target moving from about $3.06 to roughly $2.31. They cite softer revenue expectations into fiscal 2027, even as profitability metrics improved and future P/E assumptions reset to more conventional levels.Uppdatering av berättelse • Jun 25
SLQT: FY26 Guidance Reaffirmation Will Support Future P/E Re Rating
Analysts have adjusted their SelectQuote price target to reflect updated assumptions for discount rate, expected revenue growth of 2.67%, profit margin of 11.06% and a forward P/E of 1.57x. This results in a revised fair value estimate of $1.25 per share, unchanged from the prior $1.25.
Uppdatering av berättelse • Jun 06
SLQT: Earnings Outlook And Margin Improvement Will Support Future Upside Potential
Analysts have revised their SelectQuote price target to $5.00 to reflect updated assumptions, including a slightly lower revenue growth outlook, a modestly higher profit margin, and a revised discount rate and forward P/E that together indicate a more measured risk and valuation profile. What's in the News SelectQuote reaffirmed earnings guidance for Fiscal Year 2026, with revenue expected in a range of US$1.61b to US$1.71b.Uppdatering av berättelse • May 21
SLQT: Local Franchise Rollout And FY26 Guidance Will Support Future P/E Re Rating
Analysts have adjusted their price target on SelectQuote to $1.25, with the change mainly tied to updated assumptions for the discount rate, revenue growth, profit margin, and future P/E rather than a shift in their overall fair value estimate. What's in the News SelectQuote reaffirmed its earnings guidance for Fiscal Year 2026, calling for revenue in a range of US$1.61b to US$1.71b (Key Developments).Uppdatering av berättelse • May 04
SLQT: Reset Assumptions And Profit Margin Focus Will Support Future Upside Potential
SelectQuote’s updated analyst price target has moved to $5.00. Analysts cite adjustments to discount rates, revenue growth assumptions, profit margin expectations, and a revised future P/E of 5.76 as key drivers of the change.Uppdatering av berättelse • Apr 20
SLQT: Local Franchise Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote by $1 to $2, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions as the drivers of this shift. Analyst Commentary Bearish analysts cutting price targets by $1 to $2 are signaling that they see less room for upside in SelectQuote at current levels.Uppdatering av berättelse • Apr 06
SLQT: Reset Expectations And Pharmacy Agreement Will Support Future Upside
Analysts trimmed their SelectQuote price targets by $1 to $2, citing updated assumptions around discount rates, profit margins and long term P/E expectations that indicate a more cautious outlook on the shares. Analyst Commentary Recent research updates point to a more measured stance on SelectQuote, with price targets trimmed by $1 to $2 as analysts revisit their assumptions around discount rates, profit margins and long term P/E levels.Uppdatering av berättelse • Mar 22
SLQT: Pharmacy Agreement And Local Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote, with recent Street research indicating cuts of $1 and $2 to reflect revised assumptions around fair value, required return, growth and future P/E expectations. Analyst Commentary Recent Street research highlights a more cautious tone around SelectQuote, with bearish analysts trimming price targets by $1 and $2 to align with their updated assumptions on fair value, required return, growth and future P/E expectations.Uppdatering av berättelse • Mar 07
SLQT: Reset Expectations And New Pharmacy Agreement Will Support Future Upside
Narrative Update on SelectQuote The consensus analyst price target for SelectQuote has been reduced by a few dollars as analysts reassess their models following recent cuts of $1 and $2 highlighted in new Street research. Analyst Commentary Recent research highlights that the revised price targets reflect updated views on SelectQuote's execution risks and potential for improvement, rather than a complete shift in sentiment.Uppdatering av berättelse • Feb 21
SLQT: Rebased Expectations And New Pharmacy Agreement Will Support Future Upside
Analysts have trimmed their price targets on SelectQuote, with recent cuts of $1 and $2 contributing to a reduction in our fair value estimate from $4.50 to about $3.06 as they factor in adjusted growth, profitability, and risk assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price targets as reflecting updated expectations on growth and profitability rather than a fundamental change in the long term opportunity, which they still factor into their models.Uppdatering av berättelse • Feb 07
SLQT: Reset Assumptions And Pharmacy Agreement Will Support Future Upside Potential
Analysts have lowered their fair value estimate for SelectQuote from US$7.00 to US$5.00. This change reflects updated assumptions around higher discount rates, more modest revenue growth, slimmer profit margins and a higher future P/E multiple.Analysartikel • Feb 06
SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the SelectQuote, Inc. ( NYSE:SLQT ) share price has dived 27% in the last thirty...Seeking Alpha • Feb 01
SelectQuote Q2 Earnings Preview: Sell The Medicare Reimbursement News (Rating Downgrade)
Summary SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT’s fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins. Despite low EBITDA multiples, SLQT’s reliance on insurer commissions and worsening industry outlook justify caution ahead of Q2 earnings. Read the full article on Seeking AlphaUppdatering av berättelse • Jan 23
SLQT: Future Pharmacy Agreement Will Likely Support P/E Re Rating
Analysts have trimmed their price target on SelectQuote to US$2.00 from US$2.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E. Together these factors point to a slightly adjusted risk and earnings profile without changing the headline fair value figure.Uppdatering av berättelse • Jan 09
SLQT: Future Profitability Shift Will Likely Unlock Deep P/E Re Rating
Analysts have reduced their price target on SelectQuote, citing a lower fair value estimate and higher discount rate, even as updated assumptions point to a higher profit margin and a much lower future P/E multiple of about 2.1x versus 26.2x previously. Valuation Changes The Fair Value Estimate was reduced from 3.0 to 2.0, indicating a lower assessed intrinsic value per share.Uppdatering av berättelse • Dec 19
SLQT: Expanded Senior Support Services Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote, citing a slightly higher discount rate and marginally improved long term profitability assumptions. Together, these factors support an incremental increase in estimated equity value of roughly a few cents per share.Uppdatering av berättelse • Dec 05
SLQT: Expanded Senior Support Partnerships Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote by refining their discount rate assumptions and reaffirming steady long term revenue growth and profit margin expectations. This has resulted in an updated fair value estimate that is now closer to fundamentals, though it still implies limited upside from current levels.Uppdatering av berättelse • Nov 21
SLQT: Expanding Senior Referral Program Will Drive Broader Long-Term Support
Analysts have lowered their price target for SelectQuote from $5.00 to $4.50 per share. They cited changes in profit margin forecasts and a higher discount rate as key factors in the revised outlook.Analysartikel • Nov 15
Investors Give SelectQuote, Inc. (NYSE:SLQT) Shares A 26% Hiding
The SelectQuote, Inc. ( NYSE:SLQT ) share price has fared very poorly over the last month, falling by a substantial...Uppdatering av berättelse • Nov 07
SLQT: Expanded Senior Services Will Unlock Long-Term Upside Despite Legal Risks
SelectQuote Price Target Lowered Amid Revised Analyst Outlook Analysts have reduced SelectQuote's price target from $5.25 to $5.00, citing updated forecasts of slower revenue growth and reduced profit margins. What's in the News SelectQuote announced a milestone partnership with Findhelp, which will enable the company to direct over 200,000 low-income seniors to free and discounted social services such as food assistance, housing aid, transportation, healthcare, and financial or legal counseling (Key Developments).Analysartikel • Aug 31
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 30% But Many Are Still Ignoring The Company
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...Analysartikel • Jul 16
SelectQuote, Inc. (NYSE:SLQT) Could Be Riskier Than It Looks
When close to half the companies operating in the Insurance industry in the United States have price-to-sales ratios...Seeking Alpha • Apr 28
SelectQuote: Better Fundamentals Due To Medicare Advantage Reimbursement Rate Increase (Rating Upgrade)
Summary I'm upgrading SelectQuote to a buy rating after the stock's recent sharp fall. The federal government recently approved a 5.06% reimbursement rate increase for Medicare Advantage plans, which should translate into more aggressive marketing from carriers. This will lead to stronger demand and referral fees for SelectQuote, similar to how the government's premium increase approvals helped EverQuote in the auto insurance industry. SelectQuote is a value stock at <8x forward adjusted EBITDA. Read the full article on Seeking Alpha
Ny berättelse • Mar 26
Agent Efficiency And Medicare Services Will Transform 2025 Outlook
Improved agent efficiency and optimized marketing reduced expenses, boosting productivity and potentially enhancing margins and earnings.Seeking Alpha • Feb 11
SelectQuote: Better Prospects After Bain Deal, But Don't Rush To Buy (Upgrade)
Summary SelectQuote, Inc. skyrocketed ~30% after posting very strong Q2 results alongside the announcement of a $350 million private infusion from investors led by Bain Capital. Revenue grew 19% year-over-year to $481.1 million, with the Senior division and Health Services arm showing notable improvements in efficiency and subscriber growth. Despite a $350 million investment to reduce debt, SelectQuote remains highly leveraged, and SLQT stock's valuation is not compelling enough to warrant a bullish stance. I'd need to see a turnaround in profitability for the SelectRx division (better than the ~1% adjusted EBITDA margins seen in Q2) to consider buying SLQT stock. Read the full article on Seeking AlphaAnalysartikel • Jan 18
SelectQuote, Inc. (NYSE:SLQT) Soars 36% But It's A Story Of Risk Vs Reward
Despite an already strong run, SelectQuote, Inc. ( NYSE:SLQT ) shares have been powering on, with a gain of 36% in the...Analysartikel • Nov 20
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 29% But Many Are Still Ignoring The Company
Those holding SelectQuote, Inc. ( NYSE:SLQT ) shares would be relieved that the share price has rebounded 29% in the...Analysartikel • Nov 07
SelectQuote, Inc. (NYSE:SLQT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.50
It's been a pretty great week for SelectQuote, Inc. ( NYSE:SLQT ) shareholders, with its shares surging 17% to US$2.34...Analysartikel • Oct 03
SelectQuote, Inc. (NYSE:SLQT) Might Not Be As Mispriced As It Looks After Plunging 49%
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a horrible month, losing 49% after a relatively good period beforehand...Analysartikel • Jul 02
SelectQuote, Inc. (NYSE:SLQT) Doing What It Can To Lift Shares
When you see that almost half of the companies in the Insurance industry in the United States have price-to-sales...Analysartikel • Feb 13
Investors Still Aren't Entirely Convinced By SelectQuote, Inc.'s (NYSE:SLQT) Revenues Despite 29% Price Jump
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$12m |
| Mar 31 2026 | n/a | n/a | US$21m |
| Dec 31 2025 | n/a | n/a | US$20m |
| Sep 30 2025 | n/a | n/a | US$22m |
| Jun 30 2025 | US$3m | US$557k | US$25m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | n/a | n/a | -US$14m |
| Sep 30 2024 | n/a | n/a | -US$48m |
| Jun 30 2024 | US$3m | US$541k | -US$34m |
| Mar 31 2024 | n/a | n/a | -US$51m |
| Dec 31 2023 | n/a | n/a | -US$50m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | US$3m | US$525k | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$115m |
| Dec 31 2022 | n/a | n/a | -US$132m |
| Sep 30 2022 | n/a | n/a | -US$292m |
| Jun 30 2022 | US$3m | US$525k | -US$298m |
| Mar 31 2022 | n/a | n/a | -US$193m |
| Dec 31 2021 | n/a | n/a | -US$151m |
| Sep 30 2021 | n/a | n/a | US$77m |
| Jun 30 2021 | US$3m | US$500k | US$125m |
| Mar 31 2021 | n/a | n/a | US$143m |
| Dec 31 2020 | n/a | n/a | US$129m |
| Sep 30 2020 | n/a | n/a | -US$12m |
| Jun 30 2020 | US$4m | US$326k | -US$18m |
Ersättning vs marknad: Tim s total kompensation ($USD 3.49M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 652.98K ).
Ersättning vs inkomst: Ersättningen för Tim har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Tim Danker (53 yo)
9.7yrs
Anställning
US$3,487,527
Kompensation
Mr. Timothy Robert Danker, also known as Tim, serves as Chief Executive Officer and Director at SelectQuote, Inc. since 2017. Mr. Danker served as the President of the SelectQuote’s Life Division from 2016...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 9.7yrs | US$3.49m | 1.69% $ 1.5m | |
| President | 4.9yrs | US$3.06m | 2.75% $ 2.4m | |
| Chief Financial Officer | 4.3yrs | US$2.17m | 0.29% $ 258.4k | |
| Chief Operating Officer | 7.7yrs | US$2.72m | 2.58% $ 2.3m | |
| General Counsel & Corporate Secretary | 6.9yrs | US$1.61m | 0.24% $ 207.9k | |
| Chief Accounting Officer | 6.1yrs | inga uppgifter | 0.078% $ 68.8k | |
| Chief Communications & Investor Relations Officer | no data | inga uppgifter | inga uppgifter | |
| Chief Marketing Officer | 2.4yrs | inga uppgifter | 0.070% $ 62.2k | |
| Chief Medical Officer & Member of Healthcare Advisory Board | 4.1yrs | inga uppgifter | inga uppgifter | |
| President of SelectQuote Senior | no data | inga uppgifter | 0.44% $ 388.4k | |
| Executive Vice President of Healthcare Pharmacy Services | 2.2yrs | inga uppgifter | 0.063% $ 56.0k |
4.9yrs
Genomsnittlig anställningstid
50yo
Genomsnittlig ålder
Erfaren ledning: SLQT s ledningsgrupp anses vara erfaren ( 4.9 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 9.7yrs | US$3.49m | 1.69% $ 1.5m | |
| Chief Medical Officer & Member of Healthcare Advisory Board | 4.5yrs | inga uppgifter | inga uppgifter | |
| Independent Chairman | 12.7yrs | US$225.00k | 0.29% $ 256.6k | |
| Independent Director | 12.7yrs | US$207.50k | 0.29% $ 256.6k | |
| Independent Director | 1.6yrs | US$150.33k | 0.0054% $ 4.7k | |
| Independent Director | 6.6yrs | US$245.00k | 0.21% $ 183.6k | |
| Independent Director | 1.6yrs | US$150.33k | 0.0054% $ 4.7k | |
| Independent Director | 6.6yrs | US$225.00k | 0.21% $ 181.6k | |
| Independent Director | 6yrs | US$215.00k | 0.21% $ 181.6k | |
| Member of Healthcare Advisory Board | 4.5yrs | inga uppgifter | inga uppgifter | |
| Member of Healthcare Advisory Board | 4.5yrs | inga uppgifter | inga uppgifter | |
| Member of Healthcare Advisory Board | 4.5yrs | inga uppgifter | inga uppgifter |
5.3yrs
Genomsnittlig anställningstid
53yo
Genomsnittlig ålder
Erfaren styrelse: SLQT s styrelse anses vara erfaren ( 5.3 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/13 03:22 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2026/06/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
SelectQuote, Inc. bevakas av 10 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Steven Valiquette | Barclays |
| Daniel Grosslight | Citigroup Inc |
| George Sutton | Craig-Hallum Capital Group LLC |